COVID-19 Clinical Trial
Official title:
Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Angiotensin II Type 1 Receptor Blockers (ARBs) on Outcomes of Coronavirus Infection?
The coronavirus (COVID-19) pandemic continues to grow exponentially. Angiotensin II levels
are increased in human influenza and are associated with influenza viral load, disease
progression and mortality. Preliminary data shows angiotensin II receptor blockers (ARBs)
limits lung injury in murine influenza H7N9, as well as viral titre and RNA. ARBs could limit
viral titre and organ injury in COVID-19. We will therefore collect clinical chart data and
test angiotensin II levels of patients who are admitted to ICU with COVID-19 to determine
whether there is a correlation between taking ARBs and clinical outcomes in these patients.
Other blood biomarkers and clinical risk factors for COVID-19 have come to light in recent
weeks. We include these in our observational analysis to help generate an understanding of
COVID-19 presentation and blood biomarker characterization of disease.
Purpose: To determine whether angiotensin II receptor blockers (ARBs) decrease severity or
mortality in hospitalized COVID-19 infected adults.
Main Hypothesis: Modulation of ACE2 by ARBs decreases the need for hospitalization, severity
(need for ventilation, vasopressors, extracorporeal membrane oxygenation or renal replacement
therapy) or mortality of hospitalized COVID-19 infected adults.
Secondary Hypotheses:
- Plasma angiotensin I and II and other biomarker levels are associated with effectiveness
of ARBs in hospitalized COVID-19 adults
- Modulation of ACE2 by angiotensin type I receptor blockers is associated with decreased
rate of hospitalization for COVID-19
- In patients already on ARBs when they are hospitalized continuing ARBs is associated
with decreased World Health Organization (WHO) COVID-19 ordinal outcome scale
Justification: The COVID-19 epidemic continues to grow exponentially affecting over 71,429
individuals with 1775 deaths (February 17, 2020), mostly in China but also in other
countries. The population mortality rate is 2% (lower than SARS (10%) and MERS (36%) but is
10% in hospitalized and 24% in ICU-admitted COVID-19 patients in China. Recent data from
China (not yet public domain) suggest ICU mortality is higher (J. Marshall personal
communication). Interventions to date include quarantine, isolation and usual clinical care.
There are no proven antiviral or host modulating interventions for COVID-19. Notably,
critically ill COVID-19 patients have similar mortality rates as sepsis and acute respiratory
distress syndrome. Cohort studies have shown that patients already on angiotensin-converting
enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) have lower sepsis
mortality. Angiotensin II worsens lung injury in influenza models because ACE2 is
downregulated in H1N1, H5N1, H7N9, and SARS viral infections leading to increased angiotensin
II. Angiotensin II levels are increased in human influenza and are associated with influenza
viral load, disease progression and mortality. Preliminary data shows ARBs limits lung injury
in murine influenza H7N9, as well as viral titre and RNA. ARBs could limit viral titre and
organ injury in COVID-19.
Research Design:
Prospective clinical chart review: we will collect clinical data on the participant
throughout their hospital stay. Includes collection of baseline characteristics such as age,
sex, heart rate, respiratory rate, temperature, blood pressure, SaO2, respiratory
(PaO2/FiO2), renal (creatinine) and hepatic (bilirubin) function, use of oxygen,
vasopressors, ventilation and RRT. They will be followed daily throughout their hospital
stay, until death or discharge. Using left over clinical blood collected upon admission to
hospital, plasma angiotensin I and II and other biomarker levels will be measured in our
research laboratories.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
| Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
| Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
| Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
| Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
| Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
| Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
| Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
| Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
| Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
| Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
| Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
| Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
| Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
| Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
| Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
| Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|